CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping

Haslbauer JD 1 , Lindner S 2 , Valbuena-Lopez S 3 , Zainal H 4 , Zhou H 5 , D'Angelo T 6 Show all authors , Pathan F 7 , Arendt CA 8 , Bug G 2 , Serve H 2 , Vogl TJ 9 , Zeiher AM 10 , Carr-White G 11 , Nagel E 1 , Puntmann VO 12

Affiliations 

  • 1 Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
  • 2 Department of Haematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
  • 3 Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, University Hospital La Paz, Madrid, Spain
  • 4 Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, Universiti Teknologi MARA (UiTM), Sg. Buloh, Malaysia
  • 5 Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Radiology, XiangYa Hospital, Central South University, Changsha, Hunan, China
  • 6 Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Biomedical Sciences and Morphological and Functional Imaging, G. Martino University Hospital Messina, Italy
  • 7 Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, Menzies Institute for Medical Research, University of Tasmania, Australia
  • 8 Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Radiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
  • 9 Department of Radiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
  • 10 Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany
  • 11 Department of Cardiology, Guys and St Thomas' NHS Trust, London, United Kingdom
  • 12 Institute of Experimental and Translational Cardiac Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, Guys and St Thomas' NHS Trust, London, United Kingdom. Electronic address: [email protected]
Int J Cardiol, 2019 Jan 15;275:179-186.
PMID: 30360992 DOI: 10.1016/j.ijcard.2018.10.023

Abstract

BACKGROUND: Cancer-related treatment is associated with development of heart failure and poor outcome in cancer-survivors. T1 and T2 mapping by cardiovascular magnetic resonance (CMR) may detect myocardial injury due to cancer-related treatment.

METHODS: Patients receiving cancer-related treatment regimes underwent screening of cardiac involvement with CMR, either within 3 months (early Tx) or >12 months (late Tx) post-treatment. T1 and T2 mapping, cardiac function, strain, ischaemia-testing, scar-imaging and serological cardiac biomarkers were obtained.

RESULTS: Compared to age/gender matched controls (n = 57), patients (n = 115, age (yrs): median(IQR) 48(28-60), females, n = 60(52%) had reduced left ventricular ejection fraction (LV-EF) and strain, and higher native T1 and T2. The early Tx group (n = 52) had significantly higher native T1, T2 and troponin levels compared to the late Tx group, indicating myocardial inflammation and oedema (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications